Notices. DEPARTMENT OF HEALTH AND HUMAN SERVICES

564 words·~3 min read·/register/2002/10/02/02-24969

A research copy — for the controlling text, always check the official state or federal source. Not legal advice.

BILLING CODE 4140-01-M DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meetings Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. *Name of Committee:* National Institute on Drug Abuse and Initial Review Group Treatment Research Subcommittee. *Date:* October 8-9, 2002. *Time:* 9 a.m. to 5 p.m. *Agenda:* To review and evaluate grant applications. *Place:* Radisson Barcelo Hotel, 2121 P Street, NW., Washington, DC 20037. *Contact Person:* Kesinee Nimit, MD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547,

(301)435-1432. *Name of Committee:* National Institute on Drug Abuse Initial Review Group Health Services Research Subcommittee. *Date:* October 8-9, 2002. *Time:* 9 a.m. to 5 p.m. *Agenda:* To review and evaluate grant applications. *Place:* Radisson Barcelo Hotel, 2121 P Street, NW., Washington, DC 20037. *Contact Person:* Marina L. Volkov, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547,

(301)435-1433. *Name of Committee:* National Institute on Drug Abuse Initial Review Group Medication Development Research Subcommittee. *Date:* October 21-22, 2002. *Time:* 8:30 a.m. to 6 p.m. *Agenda:* To review and evaluate grant applications. *Place:* Wyndham City Center Hotel, Dupont Room, 1143 New Hampshire Avenue, NW., Washington, DC 20037. *Contact Person:* Khursheed Asghar, PhD, Chief, Basic Sciences Review Branch, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547,

(301)443-2620. *Name of Committee:* National Institute on Drug Abuse Initial Review Group, Training and Career Development Subcommittee. *Date:* November 12-14, 2002. *Time:* 9 a.m. to 6 p.m. *Agenda:* To review and evaluate grant applications. *Place:* Hyatt Arlington, 1325 Wilson Boulevard, Arlington, VA 22209. *Contact Person:* Mark Swieter, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547,

(301)435-1389. *Name of Committee:* National Institute on Drug Abuse Special Emphasis Panel Centers Review Committee. *Date:* November 18-19, 2002. *Time:* 8:30 a.m. to 5 p.m. *Agenda:* To review and evaluate grant applications. *Place:* Ritz Carlton—Pentagon City, 1250 South Hayes Street, Arlington, VA 22202. *Contact Person:* Rita Liu, PhD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20892-9547,

(301)435-1388. (Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, National Institutes of Health, HHS) Dated: September 21, 2002. LaVerne Y. Stringfield, Director, Office of Federal Advisory Committee Policy. [FR Doc. 02-24969 Filed 10-1-02; 8:45 am]